Publications scientifiques

Depuis le 15/05/2025
  1. Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients: A Nationwide Population-Based Cohort Study.
    Gautier P, Elbaz M, Bezin J, Delmas C, Cherbi M, Bouisset F, Vindis C, Renoux A, Lafaurie M, Montastruc F.
    JACC Heart Fail. 2025
  2. Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  3. The safety profile of fluoroquinolones.
    Jonville-Béra AP, Largeau B, di Meglio F, Pariente A.
    Infect Dis Now. 2025
  4. Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance.
    Crisafulli S, Bate A, Brown JS, Candore G, Chandler RE, Hammad TA, Lane S, Maro JC, Norén GN, Pariente A, Russom M, Salas M, Segec A, Shakir S, Spini A, Toh S, Tuccori M, van Puijenbroek E, Trifirò G; Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance.
    Drug Saf. 2025
  5. The latest updates on the proper use of fluoroquinolones - Actualisation 2025 update by the SPILF and the GPIP.
    Vuotto F, Bru JP, Canaoui E, Caseris M, Chopin MCC, Cohen R, Diamantis S, Dihn A, Fillatre P, Gauzit R, Gillet Y, Jonville-Bera AP, Lafaurie M, Lesprit P, Lorrot M, Lourtet J, Maulin L, Poitrenaud D, Pariente A, Raymond J, Strady C, Stahl JP, Varon E, Welker Y, Bonnet E.
    Infect Dis Now. 2025
  6. Gloves Standards and Occupational Exposure to Antineoplastic Drugs in the European Context.
    Swierczynski G, Canal-Raffin M, Tuduri L.
    Health Sci Rep. 2025
  7. Changes in the Ambulatory Use of Antibiotics in France Due to the COVID-19 Pandemic in 2020-2022: A Nationwide Time-Series Analysis.
    Rousselot N, Brayan T, Dumartin C, Clément M, Pariente A.
    Ann Fam Med. 2025
  8. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demorgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  9. Second primary cancers and hormonal therapies for prostate cancer: A nested case-control study.
    Scailteux LM, Bezin J, Gundelwein M, Edeline J, Oger E, Balusson F, Pariente A.
    Fundam Clin Pharmacol. 2025
  10. Guidelines and Best Practices for the Use of Targeted Maximum Likelihood and Machine Learning When Estimating Causal Effects of Exposures on Time-To-Event Outcomes.
    Talbot D, Diop A, Mésidor M, Chiu Y, Sirois C, Spieker AJ, Pariente A, Noize P, Simard M, Luque Fernandez MA, Schomaker M, Fujita K, Gnjidic D, Schnitzer ME.
    Stat Med. 2025
  11. Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study.
    Bernardeau C, Revol B, Salvo F, Fusaroli M, Raschi E, Cracowski JL, Roustit M, Khouri C.
    Drug Saf. 2025
  12. Psychoactive cocktail consumption on Reunion Island: A case report.
    Guyon J, Maillot A, Bastard S, Weisse F, Daveluy A, Mété D.
    J Anal Toxicol. 2025
  13. Impact of psychedelics on craving in addiction: A systematic review.
    Chapron SA, Bonazzi G, Di Lodovico L, de Ternay J, Landmann C, Nourredine M, Salvo F, Sessa B, Das R, Rolland B, Garcia-Romeu A, Auriacombe M.
    J Psychopharmacol. 2025
  14. Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study.
    Bezin J, Bénard-Laribière A, Hucteau E, Tournier M, Montastruc F, Pariente A, Faillie JL.
    EClinicalMedicine. 2024
  15. Successful Linkage of Electronic Medical Records and National Health Data System in Type 2 Diabetes Research: Methodological Insights and Implications.
    Goff RL, Brice S, Contini A, Boussac M, Souche A, Belloc F, Coulombel N, Collin C, Gouverneur A, Molimard M.
    Pharmacoepidemiol Drug Saf. 2025
  16. Ethics and clinical research: How can the Ethics Committees (CPPs) and Committees for Research Ethics (CER) evolve?
    Berdaï D, Guérin A, Pérol D, Girault C, Molimard M, Amiel P, Beaussier H, Bertoye PH, Cornu C, Deplanque D, Dreyfuss D, Duchossoy L, Fouret C, Haaser T, Le Louarn A, Rifai S, Thierry JP.
    Therapie. 2025
  17. Shaping the future of pharmacoepidemiology in France: Recommendations from the SFPT Pharmacoepidemiology Working Group.
    Soeiro T, Allouchery M, Bene J, Bezin J, Dolladille C, Faillie JL, Grimaldi L, Kaguelidou F, Khouri C, Lafaurie M, Largeau B, Montastruc F, Morin L, Scailteux LM, Pariente A; SFPT Pharmacoepidemiology Working Group.
    Therapie. 2024
  18. The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline.
    Fusaroli M, Salvo F, Khouri C, Raschi E.
    Front Pharmacol. 2024
  19. Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.
    Boulefaa D, Bagheri H, Salvo F, Rabier MB, Geniaux H, Lepelley M, Rocher F, Mahe J, Grandvillemuin A, Thai-Van H.
    Drug Saf. 2025
  20. The enhanced national pharmacovigilance system implemented for COVID-19 vaccines in France: A 2-year experience report.
    Crommelynck S, Grandvuillemin A, Ferard C, Mounier C, Gault N, Pierron E, Jacquot B, Vaillant T, Chatelet IPD, Jacquet A, Salvo F, Alt M, Bagheri H, Micallef J, Pariente A, Gautier S, Valnet-Rabier MB, Atzenhoffer M, Lepelley M, Cottin J, Lacroix I, Gras V, Massy N, Dhanani A, Vella P, Shaim Y, Baril L, Jonville-Béra AP, Benkebil M; 30 French Regional Pharmacovigilance Centres.
    Therapie. 2024